返回列表 发帖

OG-129 (No discussion)

129. The pharmaceutical industry argues that because new drugs will not be developed unless heavy development costs can be recouped in later sales, the current 20 years of protection provided by patents should be extended in the case of newly developed drugs. However, in other industries new-product development continues despite high development costs, a fact that indicates that the extension is unnecessary.

Which of the following, if true, most strongly supports the pharmaceutical industry's argument against the challenge made above?

(A) No industries other than the pharmaceutical industry have asked for an extension of the 20-year limit on patent protection.

(B) Clinical trials of new drugs, which occur after the patent is granted and before the new drug can be marketed, often now take as long as 10 years to complete.

(C) There are several industries in which the ratio of research and development costs to revenues is higher than it is in the pharmaceutical industry.

(D) An existing patent for a drug does not legally prevent pharmaceutical companies from bringing to market alternative drugs, provided they are sufficiently dissimilar to the patented drug. B

(E) Much recent industrial innovation has occurred in products---for example, in the computer and electronics industries---for which patent protection is often very ineffective.

129.

The pharmaceutical industry’s argument is best supported by an explanation of why the patent period sufficient for other industries to recoup their development costs is insufficient for the pharmaceutical industry. Choice B is the best answer because it provides an explanation: required clinical trials prevent new drugs from being sold for much of the time they receive patent protection.

Choice A is incorrect: the fact that the pharmaceutical industry’s request is unique does nothing to justify that request. Choice C and E, if true, could undermine the pharmaceutical industry’s argument, so they are incorrect. Choice D indicates that alternative drugs might render patent protection worthless, but that is clearly no reason to extend the protection.

不太看得懂OG的解释, for A and B

收藏 分享

A不正确,因为,这个行业唯一,不能证明他延长保护期的要求。B给出了该行业提出这个要求的解释,其实就是说一般在临床实验和真是投放市场之间有10的时间,而保护期是20年,那么其中有10的时间是浪费掉的,实际的保护期只有10年,比起规定的20年用来收回成本的保护期实际上短了,那么成本可能就收不回来的所以要延长。
把所有的困苦都看做是有意义的,是生命对你的磨练,也许,是为了让你成大事而做准备。

TOP

b 是加强,但是文章要求的是对这个计划进行weaken说这个计划不行。

c Other companies 是无关的,不是文章讲的,题目要求的是就该公司的计划进行weaken。

d 只是一个一般的叙述,讲了一下,和这个计划相关的内容,可不可以联系没productivity稳定是没什么直接关系的,说不定不联系,一样很高的productivity.

It is not only a test! It is Beyond GMAT!
Robert Zhou
http://weibo.com/irobert

TOP

明白了,谢谢两位!!!

TOP

返回列表

站长推荐 关闭


美国top10 MBA VIP申请服务

自2003年开始提供 MBA 申请服务以来,保持着90% 以上的成功率,其中Top10 MBA服务成功率更是高达95%


查看